Condition
Solid Organ Cancers
Estimated Enrollment: 36
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 151060
Study First Received: March 2, 2016
Last Updated: June 17, 2016
Estimated Primary Completion Date: March 2018
Primary Outcome Measures:
Number of participants with treatment-related adverse events as defined by CTCAE v4.03.|The presence of GL-ONC1 within malignant tumors by examination of the resected surgical specimen.|The maximum concentration (Cmax) of GL-ONC1 in blood after administration|Level of anti-vaccinia neutralizing antibodies in serum|Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue
Sponsors and Collaborators:
Kaitlyn Kelly, MD|Genelux Corporation|University of California, San Diego
Website Link: https://ClinicalTrials.gov/show/NCT02714374
